Reinventing Gene Editing for Safer, More Precise Therapies

Reinventing Gene Editing for Safer, More Precise Therapies

Amanda Smith, PhDCEO, Pencil Biosciences Amanda Smith, PhD, is the CEO of Pencil Biosciences, an early-stage biotechnology company reimagining gene editing by building novel editors from the ground up. Prior to leading Pencil, she held scientific, intellectual property, and innovation roles across academia, pharma, and biotech, including positions at a U.K.-based gene editing company, Horizon Discovery (now part of Revvity), and Sanofi. Today, s…